Invasive Fungal Infections Clinical Trial
Official title:
Blood Biomarkers Versus Blood Culture for Early Differentiation Between Fungal and Bacterial Infections in Pediatric Cancer Patients at South Egypt Cancer Institute
This work aims to: 1. Validate the performance of CRP, and PCT in early differentiating IFI from bacterial bloodstream infections. 2. Compare the results of CRP and PCT with the results of β-D- glucan. 3. Find the relationship between biomarkers levels [CRP, PCT and β-D- glucan] and the results of blood culture which is the gold standard of diagnosis.
Immunocompromised children with cancer receiving chemotherapy or undergoing hematopoietic stem cell transplant (HSCT) are at high risk of infections. Invasive fungal infection (IFI) is a significant cause of morbidity and mortality. The incidence of IFI from 5.3% to 24% and the mortality rate from 18.6% to 67.6%. Definite diagnosis of fungal infection in immunocompromised patients is particularly challenging. However, the clinical presentation of IFI is not specific, especially in pediatric patients. The culture of blood is the major method to diagnose proven IFI, but the results are mostly negative, and culture is time consuming. New nonculture-based methods, including antigen-based assays, and molecular detection of fungal DNA which may allow early diagnosis and treatment of fungal infection. Molecular techniques, including DNA sequencing and polymerase chain reaction (PCR). These techniques have become more available in many laboratories; however, it lacks methodological standardization, and the results vary widely among laboratories. More attention paid to the biomarkers. 1, 3- β -D- glucan (BDG) is a component of the fungal cell wall and therefore it considered a pan-fungal detection method. Traditional biomarkers as C-reactive protein (CRP) and procalcitonin (PCT) have also been evaluated for their abilities in distinguishing IFI and other infections. In neonates, CRP levels were significantly higher in fungemia than in bacteremia, in adult patients, there was not a significant difference between the candidemia and bacteremia groups. The PCT value was markedly lower in the fungal infection group than in the bacteremia group at the onset of fever. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05749380 -
Pharmacokinetics and Safety of AmBisome and DKF-5122
|
Phase 1 | |
Not yet recruiting |
NCT02527928 -
Cost-Effectiveness of Amphotericin B
|
N/A | |
Completed |
NCT02851680 -
Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.
|
N/A | |
Completed |
NCT03572049 -
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
|
Phase 2/Phase 3 | |
Suspended |
NCT05534529 -
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
|
Phase 1 | |
Completed |
NCT04024995 -
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies
|
||
Completed |
NCT00745992 -
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients
|
||
Completed |
NCT06413056 -
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
|
Phase 4 | |
Recruiting |
NCT05130723 -
Pharmacokinetics of Fluconazole in Children (2-18 Years)
|
||
Recruiting |
NCT04157465 -
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
|
N/A | |
Completed |
NCT04122560 -
Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
|
Phase 4 | |
Completed |
NCT03262584 -
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
|
||
Completed |
NCT02678598 -
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
|
N/A | |
Completed |
NCT05491733 -
A Bioequivalence Study of APX001 High-load and Low-load Tablets
|
Phase 1 | |
Not yet recruiting |
NCT06220370 -
PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.
|
||
Completed |
NCT04777058 -
Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit
|
||
Recruiting |
NCT03583164 -
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
|
Phase 2 | |
Completed |
NCT03174457 -
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
|
||
Completed |
NCT00750737 -
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
|
Phase 3 | |
Not yet recruiting |
NCT06346951 -
Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS)
|